(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 March 2013 (28.03.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/043071 A1

(51) International Patent Classification:
C07K 14/315 (2006.01) *A61K 39/395* (2006.01)
C07K 16/24 (2006.01) *C07K 19/00* (2006.01)

(21) International Application Number:
PCT/PT2012/000036

(22) International Filing Date:
19 September 2012 (19.09.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/538,552 23 September 2011 (23.09.2011) US

(71) Applicant: **TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA** [PT/PT]; Avenida Professor Egas Moniz Edificio, Egas Moniz; Piso 2; sala A8, P-1649-028 Lisboa (PT).

(72) Inventors: **CASTANHEIRA AIRES DA SILVA, Frederico Nuno**; Rua Actor Isidoro nº26 3ºEsq, P-1900-019 Lisboa (PT). **VOLKER CÔRTE-REAL, Sofia**; Rua dos Bombeiros vol. do Dafundo nº 2 2ºJ, P-1495-714 Cruz Quebrada (PT). **FERREIRA LLORENTE GRANCHO LOURENÇO, Sara**; Urbanização Quinta das Flores, Rua Coronel Melo Antunes lote 66 4ºB, P-2745-754 Massama (PT).

(74) Agent: **VIEIRA PEREIRA FERREIRA, Maria Silvina**; Clarke, Modet & Co., rua Castilho, 50 - 9º, P-1269-163 Lisboa (PT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: MODIFIED ALBUMIN-BINDING DOMAINS AND USES THEREOF TO IMPROVE PHARMACOKINETICS

(57) Abstract: The present invention relates to compositions and methods comprising a modified albumin-binding domain to improve the pharmacokinetic properties of therapeutic molecules. The modified peptides show reduced immunogenicity and/or improved solubility. In particular, compositions and methods for enhancing therapeutic potential of protein therapeutics are provided including linking a protein albumin-binding domain, which has been modified to reduce immunogenicity and/or improve solubility, to a therapeutic protein, including therapeutic antibodies, antibody fragments, antibody single domains and/or dimers of antibody single domains. These linked polypeptides can exhibit enhanced serum half life without exacerbated immunogenicity and/or without decreased solubility, and without substantially affecting the specific binding properties of the therapeutic protein.

WO 2013/043071 A1